APSARD and Tris Pharma Announce the 2021 Tris Research Award in ADHD
News provided by
Share this article
Share this article
MONMOUTH JUNCTION, N.J., Jan. 28, 2021 /PRNewswire/ The American Professional Society of ADHD and Related Disorders ( APSARD ), a professional organization focused on improving outcomes for individuals with ADHD and their families, and Tris Pharma, Inc. ( Tris ), a specialty pharmaceutical company with a robust portfolio of approved products for the treatment of Attention Deficit Hyperactivity Disorder, have jointly announced the 2021 recipients of a multi-year research award to advance and recognize outstanding research in the field of ADHD.
The Tris Research Award recognizes innovative research that facilitates a better understanding of the diagnosis, recognition and/or treatment of ADHD and related disorders. APSARD is solely responsible for the management, decision making and oversight of this award. The 2021 recipients of the award, independently